Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults (SAGE UTI)
SAGE-UTI: Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults: a Single-blind Randomized Controlled Trial Evaluating Outcomes in UTI
The goal of this clinical trial is to compare two urine testing methods used to diagnose urinary tract infections (UTIs) in adults aged 60 years and older.
The main question this trial aims to answer is:
Does Guidance® UTI testing, compared with standard urine culture, improve patient outcomes and help healthcare providers make more appropriate antibiotic treatment decisions?
Participants will:
- Be randomly assigned to either Guidance UTI testing or standard urine culture testing.
- Provide a urine sample during their initial clinic visit.
- Complete questionnaires at the initial visit and approximately 14 and 28 days later.
Researchers will compare UTI-related repeat medical visits, emergency care, hospitalizations, new UTI diagnoses, and antibiotic treatment decisions between the two groups.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
**Background and Rationale**
Urinary tract infections (UTIs) are common among older adults, particularly those with recurrent infections or underlying urinary tract conditions. Standard urine culture has limitations, including delayed results, incomplete detection of certain pathogens, and challenges identifying infections involving multiple organisms. These limitations may contribute to empiric antibiotic prescribing, inappropriate treatment, and adverse clinical outcomes.
Guidance® UTI combines multiplex polymerase chain reaction (M-PCR) for microbial identification and resistance gene detection with pooled antibiotic susceptibility testing (P-AST). This approach provides microbial identification and antibiotic susceptibility results within approximately 48 hours of laboratory receipt.
**Trial Design**
SAGE-UTI is a prospective, multicenter, single-blind, randomized controlled trial comparing Guidance UTI testing with standard urine culture in adults aged 60 years and older presenting with suspected UTIs.
Following informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio to one of two diagnostic testing pathways:
- **Arm A - Guidance UTI:** Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.
- **Arm B - Standard Urine Culture:** Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.
All urine specimens will be processed at the Pathnostics central laboratory. Treating clinicians will receive results corresponding to the assigned diagnostic pathway and will make antibiotic treatment decisions based on clinical judgment and routine practice. Results from the alternative testing pathway will remain blinded unless disclosure is medically necessary for participant safety or appropriate clinical management.
**Trial Procedures**
Participants will undergo a baseline clinical assessment, urine specimen collection, and documentation of relevant medical history, symptoms, and antibiotic treatment.
Treating clinicians will complete a treatment decision survey following review of the assigned diagnostic results. Participants will complete follow-up assessments at approximately Days 14 and 28 to document clinical outcomes and UTI-related healthcare utilization.
Residual urine specimens will also be evaluated for exploratory urinary biomarkers, including interleukin-1 beta (IL-1β), interleukin-8 (IL-8), and neutrophil gelatinase-associated lipocalin (NGAL), to explore their relationship with diagnostic findings and clinical outcomes. These exploratory results will not be reported to treating clinicians.
**Clinical Significance**
The trial will evaluate whether Guidance UTI testing, compared with standard urine culture, improves clinical outcomes and supports more appropriate antibiotic prescribing in older adults with suspected UTIs. The findings may help inform diagnostic testing strategies, improve UTI management, and support antimicrobial stewardship.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Darshika Mistry
- Phone Number: 6482844874
- Email: dmistry@pathnostics.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Individuals ≥ 60 years old requiring evaluation for suspected urinary tract infection, whose clinical management will be impacted by the provided results, seen in outpatient urology or urogynecology specialty practice
Description
nclusion Criteria:
- Able to provide written informed consent
- Male and female subjects ≥ 60 may participate with no predetermined quotas or ratios for gender participation.
- A history of (at least one): a) recurrent UTIs (defined as ≥ 2 UTIs within a 6 month period in the last 12 months) b) urinary tract obstruction (including urinary retention or hydronephrosis) and/or urinary tract injury (i.e. nephrolithiasis, ureteral or urinary stent placement, or any urologic surgery or instrumented procedure) within the last 24 months
- Must present at the time of enrollment with clinically suspected active UTI (any lower urinary tract symptoms)
- Must have positive chemical (dipstick) urinalysis (defined as nitrite "positive" and/or leukocyte esterase > "trace" by chemical urinalysis) performed at the baseline (Day 1) visit.
- Management requires microbial identification and antibiotic sensitivities from urine
- Able to provide a urine specimen (midstream voided or catheter collected)
Exclusion Criteria:
- Subjects with indwelling catheter (suprapubic or foley) or are chronically reliant on intermittent self-catheterization
- Subjects with suspected pyelonephritis, febrile UTI, or bacteremic UTI (as indicated by one or more of the following symptoms: fever, chills, rigors, hemodynamic instability, flank pain, costovertebral angle tenderness)
- Subjects with suspected prostatitis (presence of tender, enlarged, or boggy prostate on digital rectal examination; history of prostate biopsy or surgery in previous 30 days)
- Currently receiving radiation therapy in the pelvic region
- Subjects with history of unstable, untreated, or are failing treatment for overactive bladder (either neurogenic or non-neurogenic)
- Subjects with history of bladder malignancy in the past 3 years
- Subjects that have been treated with chemotherapy in the past 3 years
- Inability to independently complete subject surveys (i.e. unable to read or hear survey questions and respond appropriately)
- Incarceration
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Arm A - Guidance UTI
Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing. |
|
Arm B - Standard Urine Culture:
Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent difference between diagnostic test arm in the number of composite negative outcomes
Time Frame: 28 days
|
Percent difference between diagnostic test arm in the number of composite negative outcomes (e.g., return visit to provider for UTI, ER visit for UTI, urgent care visit for UTI, hospitalization for UTI, new UTI diagnosis) |
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent difference between diagnostic test arm in: • The number of adverse events • The number of subjects empirically treated • The number of changes to antibiotic(s) prescribed
Time Frame: 28 days
|
Percent difference between diagnostic test arm in:
|
28 days
|
|
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject
Time Frame: 28 days
|
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject |
28 days
|
|
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)
Time Frame: 28 days
|
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s) |
28 days
|
|
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions
Time Frame: 28 days
|
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions |
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-SAGE-UTI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.